Authors
Xin Zhang, Wen Li, Zhongqing Sun, Xiaomu Wang, Changgeng Song, Xiaorui Wang, Yinuo Niu, Dong Wei, Wei Zhang, Gejuan Zhang, Bei Zhang, Ling Wang, Zhirong Liu, Jingjing Zhao, Wen Jiang
Published in
Trials. Volume 27. Issue 1. Oct 09, 2026. Epub Oct 09, 2026.
Abstract
The cerebellum plays a crucial role in cognitive processing and thus presents a promising therapeutic target for Alzheimer's disease (AD). This trial aims to evaluate the efficacy and safety of long-term, neuronavigated cerebellar intermittent theta burst stimulation (iTBS) in patients with AD.
The ACT-AD trial is a multicenter, randomized, double-blind, sham-controlled study involving 100 participants with mild-to-moderate AD across 4 centers in China. Participants will be randomized to receive either cerebellar iTBS or sham stimulation for 4 weeks (daily sessions), followed by 8 weeks of weekly maintenance sessions. The primary outcome is the change in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score from baseline to week 12. Secondary outcomes include additional clinical scales. Exploratory outcomes include electroencephalogram (EEG), blood biomarkers and magnetic resonance imaging (MRI). Statistical analysis will follow intention-to-treat principles using mixed models for repeated measures (MMRM).
The ACT-AD trial will assess the efficacy and safety of long-term, neuronavigated cerebellar iTBS in treating patients with mild-to-moderate AD.
ClinicalTrials.gov, NCT06669182. Registered on 31 October 2024.
PMID:
42855713
Bibliographic data and abstract were imported from PubMed on 10 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0